INNOVIVA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
INNOVIVA, INC. (INVA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $407.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-02-25
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $407.00K.
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $0.00.
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was $747.00K, a 24.32% decline from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $407.00K 10-K · filed 2026-02-25 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2018-12-31 | $747.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | $987.00K 10-K · filed 2020-02-19 |
| 2016-12-31 | $925.00K 10-K · filed 2019-02-19 |
| 2015-12-31 | $306.00K 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |